The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
Cancers originating in the esophagus or esophagogastric junction constitute a major global health problem. Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) or adenocarcinoma, which differ in their etiology, pathology, tumor location, therapeutics, and prognosis. In contrast to esophageal adenocarcinoma, which usually affects the lower esophagus, esophageal SCC is more likely to localize at or higher than the tracheal bifurcation. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability status, and the expression of programmed death-ligand 1, has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, ipilimumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with locally advanced esophageal or esophagogastric junction cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on the management of recurrent or metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationGlobal Cancer Incidence and Mortality Rates and Trends—An Update
Torre, L. A., Siegel, R. L., Ward, E. M., & Jemal, A. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0578 · Cited by 3,692
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Janjigian, Y. Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00797-2 · Cited by 3,041
Self-citationThe clinical evaluation of chemotherapeutic agents in cancer
Karnofsky, D. A. (1949) · Medical Entomology and Zoology · Cited by 2,933
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Self-citationFuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Self-citationAdjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,827
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Sun, J.-M., Shen, L., Shah, M. A., Enzinger, P., Adenis, A., Doi, T., Kojima, T., Metges, J.-P., Li, Z., Kim, S.-B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01234-4 · Cited by 1,635
Self-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517
ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus
Shaheen, N. J., Falk, G. W., Iyer, P. G., & Gerson, L. B. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.322 · Cited by 1,501
Amin, M. B., Edge, S. B., Greene, F. L., & American Joint Committee on Cancer (n.d.) · Cited by 1,365
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Doki, Y., Ajani, J. A., Kato, K., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C.-H., Adenis, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111380 · Cited by 1,230
Self-citationKato, K., Cho, B. C., Takahashi, M., Okada, M., Lin, C.-Y., Chin, K., Kadowaki, S., Ahn, M.-J., Hamamoto, Y., Doki, Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30626-6 · Cited by 1,213
Self-citationAssessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Al-Batran, S.-E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt, G., Homann, N., Wilhelm, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9378 · Cited by 782
Population Attributable Risks of Esophageal and Gastric Cancers
Engel, L. S., Chow, W.-H., Vaughan, T. L., Gammon, M. D., Risch, H. A., Stanford, J. L., Schoenberg, J. B., Mayne, S. T., Dubrow, R., Rotterdam, H., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg047 · Cited by 775
Kang, Y.-K., Kang, W.-K., Shin, D.-B., Chen, J., Xiong, J., Wang, J., Lichinitser, M., Guan, Z., Khasanov, R., Zheng, L., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn717 · Cited by 764
Ryan, R., Gibbons, D., Hyland, J. M. P., Treanor, D., White, A., Mulcahy, H. E., O'Donoghue, D. P., Moriarty, M., Fennelly, D., & Sheahan, K. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02176.x · Cited by 726
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Janjigian, Y. Y., Kawazoe, A., Yañez, P., Li, N., Lonardi, S., Kolesnik, O., Barajas, O., Bai, Y., Shen, L., Tang, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-04161-3 · Cited by 720
Tanner, M., Hollmén, M., Junttila, T. T., Kapanen, A. I., Tommola, S., Soini, Y., Helin, H., Salo, J., Joensuu, H., Sihvo, E., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi064 · Cited by 665
Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.002 · Cited by 612
Ford, H. E. R., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F. Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70549-7 · Cited by 595
Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5805 · Cited by 541
Shitara, K., Doi, T., Dvorkin, M., Mansoor, W., Arkenau, H.-T., Prokharau, A., Alsina, M., Ghidini, M., Faustino, C., Gorbunova, V., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30739-3 · Cited by 511
Self-citationHoms, M. Y., Steyerberg, E. W., Eijkenboom, W. M., Tilanus, H. W., Stalpers, L. J., Bartelsman, J. F., van Lanschot, J. J., Wijrdeman, H. K., Mulder, C. J., Reinders, J. G., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17272-3 · Cited by 507
Chirieac, L. R., Swisher, S. G., Ajani, J. A., Komaki, R. R., Correa, A. M., Morris, J. S., Roth, J. A., Rashid, A., Hamilton, S. R., & Wu, T. (2005) · Cancer · doi:10.1002/cncr.20916 · Cited by 495
Self-citationRüschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., Chenard, M.-P., Penault-Llorca, F., Nagelmeier, I., Schlake, W., et al. (2010) · Virchows Archiv · doi:10.1007/s00428-010-0952-2 · Cited by 486
Molecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J., & Vranic, S. (2019) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 486
Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., Takeda, M., Ohe, Y., Khan, S., Ohashi, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00541-1 · Cited by 449
Ohtsu, A., Shimada, Y., Shirao, K., Boku, N., Hyodo, I., Saito, H., Yamamichi, N., Miyata, Y., Ikeda, N., Yamamoto, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.130 · Cited by 427
A Prospective Study of Tobacco, Alcohol, and the Risk of Esophageal and Gastric Cancer Subtypes
Freedman, N. D., Abnet, C. C., Leitzmann, M. F., Mouw, T., Subar, A. F., Hollenbeck, A. R., & Schatzkin, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm051 · Cited by 421
Ancona, E., Ruol, A., Santi, S., Merigliano, S., Sileni, V. C., Koussis, H., Zaninotto, G., Bonavina, L., & Peracchia, A. (2001) · PubMed · doi:10.1002/1097-0142(20010601)91:11<2165::aid-cncr1245>3.0.co;2-h · Cited by 401
Puli, S. R., Reddy, J. B., Bechtold, M. L., Antillon, D., Ibdah, J. A., & Antillon, M. R. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1479 · Cited by 387
Dank, M., Zaluski, J., Barone, C., Valvere, V., Yalcin, S., Peschel, C., Wenczl, M., Goker, E., Cisar, L., Wang, K., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn166 · Cited by 343
Lagergren, J., Bergström, R., Lindgren, A., & Nyrén, O. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000201)85:3<340::aid-ijc8>3.0.co;2-n · Cited by 337
Cook, M. B., Kamangar, F., Whiteman, D. C., Freedman, N. D., Gammon, M. D., Bernstein, L., Brown, L. M., Risch, H. A., Ye, W., Sharp, L., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq289 · Cited by 316
Recent developments in esophageal adenocarcinoma
Lagergren, J., & Lagergren, P. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21185 · Cited by 309
Kato, H., Kuwano, H., Nakajima, M., Miyazaki, T., Yoshikawa, M., Ojima, H., Tsukada, K., Oriuchi, N., Inoue, T., & Endo, K. (2002) · Cancer · doi:10.1002/cncr.10330 · Cited by 309
Fuchs, C. S., Moore, M. R., Harker, G., Villa, L., Rinaldi, D., & Hecht, J. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.058 · Cited by 296
Fuchs, C. S., Shitara, K., Di Bartolomeo, M., Lonardi, S., Al-Batran, S.-E., Van Cutsem, E., Ilson, D. H., Alsina, M., Chau, I., Lacy, J., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30791-5 · Cited by 288
Self-citationMurphy, K. M., Zhang, S., Geiger, T., Hafez, M. J., Bacher, J., Berg, K. D., & Eshleman, J. R. (2006) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050092 · Cited by 281
Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus
Ajani, J. A., Ilson, D. H., Daugherty, K., Pazdur, R., Lynch, P. M., & Kelsen, D. P. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.14.1086 · Cited by 280
Self-citationBouché, O., Raoul, J. L., Bonnetain, F., Giovannini, M., Etienne, P. L., Lledo, G., Arsène, D., Paitel, J. F., Guérin-Meyer, V., Mitry, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.140 · Cited by 274
Guimbaud, R., Louvet, C., Ries, P., Ychou, M., Maillard, E., André, T., Gornet, J.-M., Aparicio, T., Nguyen, S., Azzedine, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1011 · Cited by 263
Okines, A. F. C., Norman, A. R., McCloud, P., Kang, Y.-K., & Cunningham, D. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp047 · Cited by 258
Bartley, A. N., Washington, M. K., Ventura, C. B., Ismaila, N., Colasacco, C., Benson, A. B., Carrato, A., Gulley, M. L., Jain, D., Kakar, S., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0331-cp · Cited by 254
Self-citationLorenzen, S., Schuster, T., Porschen, R., Al-Batran, S.-E., Hofheinz, R., Thuss-Patience, P., Moehler, M., Grabowski, P., Arnold, D., Greten, T., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp069 · Cited by 241
Willis, J., Lefterova, M. I., Artyomenko, A., Kasi, P. M., Nakamura, Y., Mody, K., Catenacci, D. V. T., Fakih, M., Barbacioru, C., Zhao, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1324 · Cited by 239
Self-citationThosani, N., Singh, H., Kapadia, A., Ochi, N., Lee, J. H., Ajani, J., Swisher, S. G., Hofstetter, W. L., Guha, S., & Bhutani, M. S. (2012) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2011.09.016 · Cited by 236
Self-citationMeredith, K. L., Weber, J. M., Turaga, K. K., Siegel, E. M., McLoughlin, J., Hoffe, S., Marcovalerio, M., Shah, N., Kelley, S., & Karl, R. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0862-1 · Cited by 234
Corley, D. A., & Buffler, P. A. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.6.1415 · Cited by 233
A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma
Turati, F., Tramacere, I., La Vecchia, C., & Negri, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mds244 · Cited by 209
Kojima, T., Muro, K., Francois, E., Hsu, C.-H., Moriwaki, T., Kim, S.-B., Lee, S.-H., Bennouna, J., Kato, K., Lin, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.2 · Cited by 202
Self-citationMakiyama, A., Sukawa, Y., Kashiwada, T., Kawada, J., Hosokawa, A., Horie, Y., Tsuji, A., Moriwaki, T., Tanioka, H., Shinozaki, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03077 · Cited by 200
Geographical distribution and racial disparity in esophageal cancer
Pickens, A., & Orringer, M. B. (2003) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(03)01202-5 · Cited by 180
Shah, M. A., Janjigian, Y. Y., Stoller, R., Shibata, S., Kemeny, M., Krishnamurthi, S., Su, Y. B., Ocean, A., Capanu, M., Mehrotra, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.7465 · Cited by 178
Al-Batran, S.-E., Pauligk, C., Homann, N., Hartmann, J. T., Moehler, M., Probst, S., Rethwisch, V., Stoehlmacher-Williams, J., Prasnikar, N., Hollerbach, S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.025 · Cited by 165
FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication
Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm560040.htm · Cited by 158
Obesity, metabolic syndrome and esophageal adenocarcinoma: Epidemiology, etiology and new targets
Ryan, A. M., Duong, M. T., Healy, L., Ryan, S. A., Parekh, N., Reynolds, J. V., & Power, D. G. (2011) · Cancer Epidemiology · doi:10.1016/j.canep.2011.03.001 · Cited by 151
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer
Janmaat, V. T., Steyerberg, E. W., van der Gaast, A., Mathijssen, R. H. J., Bruno, M. J., Peppelenbosch, M. P., Kuipers, E. J., & Spaander, M. C. W. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004063.pub4 · Cited by 150
Assersohn, L., Brown, G. M., Cunningham, D., Ward, C., Oates, J. R., Waters, J. S., Hill, M. E., & Norman, A. R. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh007 · Cited by 147
Quality of life measurement in patients with oesophageal cancer.
Blazeby, J. M., Williams, M., Brookes, S. T., et al. (1995) · Gut · doi:10.1136/gut.37.4.505 · Cited by 144
Brücher, B. L. D. M., Becker, K., Lordick, F., Fink, U., Sarbia, M., Stein, H. J., Busch, R. M., Zimmermann, F. B., Molls, M., Höfler, H., et al. (2006) · Cancer · doi:10.1002/cncr.21850 · Cited by 143
Kim, G. M., Jeung, H., Rha, S. Y., Kim, H. S., Jung, I., Nam, B., Lee, K. H., & Chung, H. C. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.017 · Cited by 140
A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson, D. H., Forastiere, A. A., Arquette, M. A., Costa, F., Heelan, R. T., Huang, Y., & Kelsen, D. P. (2000) · PubMed · Cited by 135
Self-citationGu, Y., Swisher, S. G., Ajani, J. A., Correa, A. M., Hofstetter, W. L., Liao, Z. X., Komaki, R. R., Rashid, A., Hamilton, S. R., & Wu, T. (2006) · Cancer · doi:10.1002/cncr.21693 · Cited by 132
Self-citationKato, S., Okamura, R., Baumgartner, J. M., Patel, H., Leichman, L., Kelly, K. J., Sicklick, J. K., Fanta, P. T., Lippman, S. M., & Kurzrock, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1128 · Cited by 130
Rohatgi, P. R., Swisher, S. G., Correa, A. M., Wu, T. T., Liao, Z. X., Komaki, R. U., Walsh, G. L., Vaporciyan, A. A., Lynch, P. M., Rice, D. C., et al. (2005) · Cancer · doi:10.1002/cncr.21346 · Cited by 129
Self-citationLanger, R., Ott, K., Feith, M., Lordick, F., Siewert, J., & Becker, K. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.123 · Cited by 126
Lorenzen, S., Thuss-Patience, P. C., Al‐Batran, S., Lordick, F., Haller, B., Schuster, T., Pauligk, C., Luley, K. B., Bichev, D., Schumacher, G., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt141 · Cited by 120
Wu, T., Chirieac, L. R., Abraham, S. C., Krasinskas, A. M., Wang, H., Rashid, A., Correa, A. M., Hofstetter, W. L., Ajani, J. A., & Swisher, S. G. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213312.36306.cc · Cited by 119
Self-citationGopal, D. V., Lieberman, D. A., Magaret, N. D., et al. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1024715824149 · Cited by 113
Enzinger, P. C., Burtness, B. A., Niedzwiecki, D., Ye, X., Douglas, K., Ilson, D. H., Villaflor, V. M., Cohen, S. J., Mayer, R. J., Venook, A. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5092 · Cited by 112
Self-citationPaclitaxel given by a weekly 1-h infusion in advanced esophageal cancer
Ilson, D. H., Wadleigh, R. G., Leichman, L., & Kelsen, D. P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm004 · Cited by 100
Self-citationvan Westreenen, H. L., Heeren, P. A. M., van Dullemen, H. M., van der Jagt, E. J., Jager, P. L., Groen, H., & Plukker, J. T. M. (2004) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2004.09.055 · Cited by 96
Sym, S. J., Hong, J., Park, J., Cho, E. K., Lee, J. H., Park, Y. H., Lee, W. K., Chung, M., Kim, H.-S., Park, S. H., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2027-3 · Cited by 80
Findlay, J. M., Bradley, K. M., Maile, E. J., Braden, B., Maw, J., Phillips‐Hughes, J., Gillies, R. S., Maynard, N., & Middleton, M. R. (2015) · British journal of surgery · doi:10.1002/bjs.9905 · Cited by 75
Park, Y. H., Lee, J., Ryoo, B., Ryu, M., Yang, S. H., Kim, B. S., Shin, D. B., Chang, H. M., Kim, T. W., Yuh, Y. J., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0515-7 · Cited by 70
Walker, A. J., Spier, B. J., Perlman, S. B., Stangl, J. R., Frick, T. J., Gopal, D. V., Lindstrom, M. J., Weigel, T. L., & Pfau, P. R. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0306-0 · Cited by 68
Shah, M. A., Kojima, T., Hochhauser, D., Enzinger, P. C., Raimbourg, J., Hollebecque, A., Lordick, F., Kim, S.-B., Tajika, M., Kim, H., et al. (2019) · UCL Discovery (University College London) · Cited by 66
Self-citationZhao, J., Wu, M., Kim, C. H., Jin, Z.-Y., Zhou, J., Han, R., Yang, J., Zhang, X.-F., Wang, X.-S., Liu, A., et al. (2016) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000262 · Cited by 64
PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.
Le, D. T., Uram, J. N., Wang, H., Kemberling, H., Eyring, A. D., Bartlett, B. R., Goldberg, R. M., Crocenzi, T. S., Fisher, G. A., Lee, J. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.195 · Cited by 64
Self-citationFDA approves larotrectinib for solid tumors with NTRK gene fusions
Administration, U. S. F. &. D. (2018) · Case Medical Research · doi:10.31525/fda1-ucm626720.htm · Cited by 60
Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia
Anandasabapathy, S., Jhamb, J., Davila, M. L., Wei, C., Morris, J. S., & Bresalier, R. S. (2007) · Cancer · doi:10.1002/cncr.22451 · Cited by 59
Hall, P. S., Swinson, D., Waters, J. S., Wadsley, J., Falk, S., Roy, R., Tillett, T., Nicoll, J., Cummings, S., Grumett, S. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4006 · Cited by 59
Kim, W. H., Izquierdo, L. G., Vilardell, F., Chu, K., Soucy, G., dos Santos, L. V., Monges, G. M., Viale, G., Brito, M. J., Osborne, S., et al. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000423 · Cited by 58
Barbour, A. P., Rizk, N. P., Gerdes, H., Bains, M. S., Rusch, V. W., Brennan, M. F., & Coit, D. G. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.05.010 · Cited by 55
Self-citationMunden, R. F., Macapinlac, H. A., & Erasmus, J. J. (2006) · Journal of Thoracic Imaging · doi:10.1097/00005382-200605000-00005 · Cited by 54
Moehler, M. H., Kanzler, S., Geißler, M., Raedle, J., Ebert, M., Daum, S., Flieger, D., Seufferlein, T. T. W., Galle, P. R., & Hoehler, T. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp269 · Cited by 54
Tabernero, J. M., Ohtsu, A., Muro, K., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0895 · Cited by 48
Sym, S. J., Ryu, M., Lee, J., Chang, H. M., Kim, T. W., Lee, S. S., Lee, J. S., & Kang, Y. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31815878a2 · Cited by 38
Klempner, S. J., Maron, S. B., Chase, L. M., Lomnicki, S., Wainberg, Z. A., & Catenacci, D. V. T. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0602 · Cited by 33
Self-citationFDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC
(2019) · Case Medical Research · doi:10.31525/cmr-1a554a6 · Cited by 31
Egebjerg, K., Garbyal, R. S., Hasselby, J. P., Bæksgaard, L., & Mau‐Sørensen, M. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103339 · Cited by 28
The endoscopic diagnosis and staging of oesophageal adenocarcinoma
Bergman, J. J. G. H. M. (2006) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2006.04.010 · Cited by 25
Shinozaki‐Ushiku, A., Ishikawa, S., Komura, D., Seto, Y., Aburatani, H., & Ushiku, T. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01061-9 · Cited by 25
Arnold, A., Daum, S., von Winterfeld, M., Berg, E., Hummel, M., Horst, D. A., Rau, B., Stein, U., & Treese, C. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152662 · Cited by 22
FDA approves pembrolizumab for advanced esophageal squamous cell cancer
(2019) · Case Medical Research · doi:10.31525/cmr-19086be · Cited by 17
Lustberg, M. B., Bekaii‐Saab, T., Young, D., Otterson, G. A., Burak, W. E., Abbas, A., McCracken-Bussa, B., Lustberg, M. E., & Villalona-Calero, M. A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d7776d · Cited by 16
FDA approves Lonsurf for recurrent, metastatic gastric and gastroesophageal junction adenocarcinoma
(2019) · Case Medical Research · doi:10.31525/fda1-ucm632032.htm · Cited by 1
Cited by
Yang, H., Wang, F., Hallemeier, C. L., Lerut, T., & Fu, J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02226-8 · Cited by 299
Metadata
- Authors
- Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Farjah, F., Gerdes, H., Gibson, M., Grierson, P., Hofstetter, W. L., Ilson, D. H., Jalal, S., Keswani, R. N., Kim, S., Kleinberg, L. R., Klempner, S., Lacy, J., Licciardi, F., Ly, Q. P., Matkowskyj, K. A., McNamara, M., Miller, A., Mukherjee, S., Mulcahy, M. F., Outlaw, D., Perry, K. A., Pimiento, J., Poultsides, G. A., Reznik, S., Roses, R. E., Strong, V. E., Su, S., Wang, H. L., Wiesner, G., Willett, C. G., Yakoub, D., Yoon, H., McMillian, N. R., & Pluchino, L. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2023-04
- Volume
- 21
- Issue
- 4
- Pages
- 393-422
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4362546931
- Cited by
- 569
- References
- 110
- FWCI
- 132.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.